Pharmaceutical and healthcare company Abbott Laboratories recently released its forecasted earnings for 2024, and the figures fell largely below market estimates. This news led to a drop in the company's shares, reflecting the concerns among investors.
According to Abbott, it expects its earnings for 2024 to reach approximately $5 per share. This falls short of Wall Street's average estimate of around $5.11 per share. The lower-than-expected forecast has raised questions among investors and analysts about the company's potential for growth in the upcoming years.
